Search Within

Mia DeNunzio

Formats
  1. Meeting Abstract (3)
  2. Journal Article (1)
Groups
  1. Department of Medicine (4)
  2. Genitourinary Oncology Service (4)
  3. Hematologic Malignancies, Division of (4)
  4. Solid Tumor Oncology Division (4)
  5. GSK Faculty (2)
  6. Human Oncology and Pathogenesis Program (2)

More Groups

People
  1. Dana Rathkopf (4)
  2. Howard Scher (4)
  3. Michael Morris (4)
  4. Susan Slovin (4)
  5. Daniel Danila (3)
  6. Brett Carver (2)

More People

Years
  1. 2020 (1)
  2. 2016 (1)
  3. 2014 (2)
Publications
  1. Journal of Clinical Oncology (3)
  2. Clinical Genitourinary Cancer (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Elsevier Inc. (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I trial of IGF-1R inhibitor cixutumumab and mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D. J.; Chudow, J.; DeNunzio, M.; Slovin, S. F.; Danila, D. C.; Morris, M. J.; Scher, H. I.; Rathkopf, D. E.
    Clinical Genitourinary Cancer (2020)

    Fulltext@MSK | Save
  • A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer
    Meeting Abstract

    Touijer, K. A.; Carver, B. S.; Coleman, J. A.; Laudone, V. P.; Hullings, M.; Ehrlich, S. S.; DeNunzio, M.; Reuter, V. E.; Eastham, J. A.; Danila, D. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Carver, B. S.; Chen, Y.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Autio, K. A.; DeNunzio, M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save